Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Clinical trial NCT05438420 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05438420
Sponsor: Qurient Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Esophageal Cancer Gastric Cancer Hepatocellular Cancer Cervical Cancer

Start date: 2023-01-12
Primary completion: 2027-12-30
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.